HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies.
Small interfering RNA (siRNA) represents a potent gene therapy tool, playing pivotal roles in treating cancers and genetic disorders due to its unique advantages. Chemical modifications of nucleic acids serve as critical strategies to enhance the stability and targeting capability of RNA therapeutics, while overcoming siRNA delivery hurdles predominantly relies on covalent conjugation between targeting ligands and siRNA molecules. Among various macromolecular conjugation approaches, copper-catalyzed azide–alkyne cycloaddition (CuAAC) is widely adopted owing to its high reactivity, specificity, and biocompatibility. This study focuses on the systematic optimization of CuAAC click chemistry for synthesizing trivalent targeting ligand-RNA conjugates. Through design of experiments screening, four key factors were identified: azide equivalents, oligo concentration, reaction pH, and ligand/Cu ratio. Optimal design spaces for these parameters were determined, providing a standardized solution for the large-scale production of multivalent ligand-RNA conjugates. This advancement significantly accelerates the clinical translation of RNAi therapeutics.
            We use cookies to provide a better web experience.
            By using our site, you acknowledge our use of cookies and please read our Cookie Notice for 
                More information